Nephros INC

Nephros, Inc. announced record second-quarter net revenue of $6 million, a 36% increase year-over-year, alongside a significant jump in net income to $1.2 million.

Nephros Inc. announced first-quarter 2026 financial results, showing a 7% increase in net revenue to $5.2 million, driven by core programmatic business growth, but facing margin pressure from tariffs and currency fluctuations.

Nephros, Inc. announced the posting of its updated 2026 Corporate Presentation on its corporate website via an 8-K filing.

Nephros, Inc. has entered into a new exclusive license and supply agreement with Medica S.p.A. for filtration products, replacing a prior agreement and outlining significant purchase commitments through 2030.

Nephros, Inc. announced robust second-quarter 2025 financial results, achieving $4.4 million in net revenue and its third consecutive quarter of profitability.

Nephros, Inc. announced the successful election of a director, ratification of its independent accounting firm, and advisory approval of executive compensation at its 2025 Annual Meeting of Stockholders.

Nephros, Inc. announced a significant increase in net revenue and net income for the second quarter of 2026, driven by robust product sales and a favorable tariff refund.

Nephros, Inc. announced a significant financial turnaround, reporting net income and positive operating cash flow for the third quarter and first nine months of 2025, driven by robust revenue growth.

Nephros, Inc. reported a significant increase in net revenue and a return to net income for the second quarter and first half of 2025, driven by strong product sales and improved gross margins.

Nephros, Inc. announces a profitable first quarter in 2025, driven by increased net revenue and improved gross margins compared to the same period in 2024.

Nephros Inc. experienced a decrease in revenue for the third quarter of 2024, but saw improvements in gross profit margins and a return to profitability.

Nephros Inc. experienced a decrease in revenue for the second quarter of 2024, primarily due to reduced emergency response orders, though programmatic sales showed growth.

Nephros, Inc. announced a significant increase in net income and revenue for fiscal year 2025, driven by higher programmatic sales and emergency response business, despite ongoing tariff impacts and an identified material weakness in internal controls.

Nephros, Inc. achieves its first profitable year with a net income of $0.1 million, despite a slight revenue decrease due to reduced emergency response orders.

Nephros, Inc. and Medica S.p.A. have entered into a new license and supply agreement, extending their collaboration for the marketing and supply of filtration products through December 31, 2028.

Wexford Capital Lp and 3 others reported changes in beneficial ownership of Nephros Inc common stock on September 14, 2026.

Wexford Capital Lp and 3 others reported changes in beneficial ownership of Nephros Inc common stock on August 18, 2026.

Arthur H Amron, a Director of Nephros Inc, received 2,418 shares of common stock on August 12, 2026.

Director Arthur H. Amron acquired 3,574 shares of Nephros Inc. common stock in lieu of cash board fees.

Nephros Inc. CEO Robert R. Banks Jr. exercised 120,000 stock options, increasing his direct common stock ownership to 190,000 shares.

Nephros Inc.'s Chief Financial Officer, Judy Krandel, exercised options to acquire 68,861 shares of common stock at $1.71 per share.

Nephros, Inc. has filed a definitive proxy statement with the Securities and Exchange Commission (SEC) related to its upcoming shareholder meeting.

Nephros, Inc. will hold its annual meeting virtually on June 16, 2025, to elect a director, ratify the appointment of its accounting firm, and approve executive compensation.

Nephros, Inc. has filed a definitive proxy statement with the Securities and Exchange Commission (SEC) pertaining to Section 14(a) of the Securities Exchange Act of 1934.

Nephros, Inc. is holding its annual meeting of stockholders on May 23, 2024, to vote on key proposals including the election of directors, ratification of the auditor, approval of an equity incentive plan, and an advisory vote on executive compensation.

Wexford Capital LP and associated entities have amended their Schedule 13D filing, reporting a decrease in their beneficial ownership of Nephros, Inc. common stock to 2.06%.

Charles E. Davidson and CD Holding Company, LLC have jointly filed a Schedule 13G, reporting beneficial ownership of 5.68% of Nephros, Inc. common stock.

Topline Capital Management, LLC, Collin McBirney, and Topline Capital Partners, LP have disclosed a 5.6% beneficial ownership stake in Nephros Inc. common stock.